{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:23:33Z","timestamp":1793993013084,"version":"4.8.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T00:00:00Z","timestamp":1554854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["EKFS-2014-A06"],"award-info":[{"award-number":["EKFS-2014-A06"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2016 Kolleg.19"],"award-info":[{"award-number":["2016 Kolleg.19"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00432-019-02915-1","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T19:41:16Z","timestamp":1554925276000},"page":"1651-1660","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva"],"prefix":"10.1007","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1458-7303","authenticated-orcid":false,"given":"Fabinshy","family":"Thangarajah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Pahmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Mortimer","family":"Schiffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Puppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mallmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Hamacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Buettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Alidousty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Scheel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Maria","family":"Schultheis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,10]]},"reference":[{"issue":"Suppl 1","key":"2915_CR1","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/S0020-7292(06)60028-3","volume":"95","author":"U Beller","year":"2006","unstructured":"Beller U, Quinn MA, Benedet JL, Creasman WT, Ngan HYS, Maisonneuve P, Pecorelli S, Odicino F, Heintz APM (2006) Carcinoma of the vulva. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S7\u2013S27. \n                    https:\/\/doi.org\/10.1016\/s0020-7292(06)60028-3","journal-title":"Int J Gynaecol Obstet"},{"key":"2915_CR2","doi-asserted-by":"publisher","first-page":"13506","DOI":"10.18632\/oncotarget.3642","volume":"6","author":"F Bertucci","year":"2015","unstructured":"Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L, Viens P, Birnbaum D, van Laere S (2015) PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget 6:13506\u201313519","journal-title":"Oncotarget"},{"key":"2915_CR3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlh\u00e4ufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crin\u00f2 L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"2915_CR4","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455\u20132465. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1200694","journal-title":"N Engl J Med"},{"key":"2915_CR5","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/2326-6066.CIR-15-0043","volume":"3","author":"M Callea","year":"2015","unstructured":"Callea M, Albiges L, Gupta M, Cheng S-C, Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB, Hodi FS, Choueiri TK, McDermott DF, Freeman GJ, Signoretti S (2015) Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol Res 3:1158\u20131164. \n                    https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0043","journal-title":"Cancer Immunol Res"},{"key":"2915_CR6","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu T-E, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA (2017) First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376:2415\u20132426. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1613493","journal-title":"N Engl J Med"},{"key":"2915_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2364-7","author":"M Choschzick","year":"2018","unstructured":"Choschzick M, Gut A, Fink D (2018) PD-L1 receptor expression in vulvar carcinomas is HPV-independent. Virchows Arch. \n                    https:\/\/doi.org\/10.1007\/s00428-018-2364-7","journal-title":"Virchows Arch"},{"key":"2915_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/his.12034","volume":"62","author":"M Pino Del","year":"2013","unstructured":"Del Pino M, Rodriguez-Carunchio L, Ordi J (2013) Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. Histopathology 62:161\u2013175. \n                    https:\/\/doi.org\/10.1111\/his.12034","journal-title":"Histopathology"},{"key":"2915_CR9","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5:1365\u20131369. \n                    https:\/\/doi.org\/10.1038\/70932","journal-title":"Nat Med"},{"key":"2915_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793\u2013800. \n                    https:\/\/doi.org\/10.1038\/nm730","journal-title":"Nat Med"},{"key":"2915_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11864-018-0584-3","volume":"19","author":"CA Fan","year":"2018","unstructured":"Fan CA, Reader J, Roque DM (2018) Review of immune therapies targeting ovarian cancer. Curr Treat Options Oncol 19:74. \n                    https:\/\/doi.org\/10.1007\/s11864-018-0584-3","journal-title":"Curr Treat Options Oncol"},{"key":"2915_CR12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/LGT.0b013e3182472947","volume":"16","author":"JW Gargano","year":"2012","unstructured":"Gargano JW, Wilkinson EJ, Unger ER, Steinau M, Watson M, Huang Y, Copeland G, Cozen W, Goodman MT, Hopenhayn C, Lynch CF, Hernandez BY, Peters ES, Saber MS, Lyu CW, Sands LA, Saraiya M (2012) Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine introduction. J Low Genit Tract Dis 16:471\u2013479. \n                    https:\/\/doi.org\/10.1097\/LGT.0b013e3182472947","journal-title":"J Low Genit Tract Dis"},{"key":"2915_CR13","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17:e542\u2013e551. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30406-5","journal-title":"Lancet Oncol"},{"key":"2915_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R (2018) Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 6:8. \n                    https:\/\/doi.org\/10.1186\/s40425-018-0316-z","journal-title":"J Immunother Cancer"},{"key":"2915_CR15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ygyno.2008.01.041","volume":"109","author":"M Hampl","year":"2008","unstructured":"Hampl M, Deckers-Figiel S, Hampl JA, Rein D, Bender HG (2008) New aspects of vulvar cancer: changes in localization and age of onset. Gynecol Oncol 109:340\u2013345. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2008.01.041","journal-title":"Gynecol Oncol"},{"key":"2915_CR16","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu T-E, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O\u2019Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378:2093\u20132104. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1801946","journal-title":"N Engl J Med"},{"key":"2915_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.4143\/crt.2015.249","volume":"48","author":"HS Kim","year":"2015","unstructured":"Kim HS, Lee JY, Lim SH, Park K, Sun J-M, Ko YH, Baek C-H, Y-i Son, Jeong HS, Ahn YC, Lee M-Y, Hong M, Ahn M-J (2015) Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma. Cancer Res Treat 48:527\u2013536. \n                    https:\/\/doi.org\/10.4143\/crt.2015.249","journal-title":"Cancer Res Treat"},{"key":"2915_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/1471-2407-12-223","volume":"12","author":"M Kowalewska","year":"2012","unstructured":"Kowalewska M, Radziszewski J, Goryca K, Bujko M, Oczko-Wojciechowska M, Jarzab M, Siedlecki JA, Bidzinski M (2012) Estimation of groin recurrence risk in patients with squamous cell vulvar carcinoma by the assessment of marker gene expression in the lymph nodes. BMC Cancer 12:223. \n                    https:\/\/doi.org\/10.1186\/1471-2407-12-223","journal-title":"BMC Cancer"},{"key":"2915_CR19","series-title":"World Health Organization classification of tumours","volume-title":"WHO classification of tumours of female reproductive organs","year":"2014","unstructured":"Kurman RJ (ed) (2014) WHO classification of tumours of female reproductive organs, vol 4, 4th edn. World Health Organization classification of tumours. IARC, Lyon","edition":"4"},{"key":"2915_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1586\/14737140.2015.1037837","volume":"15","author":"S Mahner","year":"2015","unstructured":"Mahner S, Prieske K, Grimm D, Trillsch F, Prieske S, von Amsberg G, Petersen C, Mueller V, Jaenicke F, Woelber L (2015) Systemic treatment of vulvar cancer. Expert Rev Anticancer Ther 15:629\u2013637. \n                    https:\/\/doi.org\/10.1586\/14737140.2015.1037837","journal-title":"Expert Rev Anticancer Ther"},{"key":"2915_CR21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.21037\/tlcr.2017.03.01","volume":"6","author":"J Malhotra","year":"2017","unstructured":"Malhotra J, Jabbour SK, Aisner J (2017) Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 6:196\u2013211. \n                    https:\/\/doi.org\/10.21037\/tlcr.2017.03.01","journal-title":"Transl Lung Cancer Res"},{"key":"2915_CR22","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.4049\/jimmunol.169.7.3581","volume":"169","author":"MM Mazanet","year":"2002","unstructured":"Mazanet MM, Hughes CCW (2002) B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 169:3581\u20133588","journal-title":"J Immunol"},{"key":"2915_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/00019606-199903000-00006","volume":"8","author":"S Merkelbach-Bruse","year":"1999","unstructured":"Merkelbach-Bruse S, Jakob C, Tietze L, Schr\u00f6der W, Rath W, F\u00fczesi L (1999) Consensus polymerase chain reaction and enzyme-linked immunosorbent assay for human papillomavirus detection and typing in cervical specimens. Diagn Mol Pathol 8:32\u201338","journal-title":"Diagn Mol Pathol"},{"key":"2915_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2011.00098","author":"G Multhoff","year":"2012","unstructured":"Multhoff G, Molls M, Radons J (2012) Chronic inflammation in cancer development. Front Immunol. \n                    https:\/\/doi.org\/10.3389\/fimmu.2011.00098","journal-title":"Front Immunol"},{"key":"2915_CR25","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, S-l Teng, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558\u2013562. \n                    https:\/\/doi.org\/10.1038\/nature13904","journal-title":"Nature"},{"key":"2915_CR26","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2147\/DDDT.S75152","volume":"9","author":"Y Qing","year":"2015","unstructured":"Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu G-L, Luo H, Yang Y-X, Dai X-Y, Zhou S-F, Wang D (2015) Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Dev Ther 9:901\u2013909. \n                    https:\/\/doi.org\/10.2147\/DDDT.S75152","journal-title":"Drug Des Dev Ther"},{"key":"2915_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/ITT.S125070","volume":"7","author":"S Raju","year":"2018","unstructured":"Raju S, Joseph R, Sehgal S (2018) Review of checkpoint immunotherapy for the management of non-small cell lung cancer. Immunotargets Ther 7:63\u201375. \n                    https:\/\/doi.org\/10.2147\/ITT.S125070","journal-title":"Immunotargets Ther"},{"key":"2915_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ygyno.2005.12.027","volume":"102","author":"F Raspagliesi","year":"2006","unstructured":"Raspagliesi F, Hanozet F, Ditto A, Solima E, Zanaboni F, Vecchione F, Kusamura S (2006) Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva. Gynecol Oncol 102:333\u2013337. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2005.12.027","journal-title":"Gynecol Oncol"},{"key":"2915_CR29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124\u2013128. \n                    https:\/\/doi.org\/10.1126\/science.aaa1348","journal-title":"Science"},{"key":"2915_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","volume":"36","author":"H Rizvi","year":"2018","unstructured":"Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD (2018) Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol 36:633\u2013641. \n                    https:\/\/doi.org\/10.1200\/JCO.2017.75.3384","journal-title":"J Clin Oncol"},{"key":"2915_CR31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/PAI.0000000000000408","volume":"24","author":"C Roach","year":"2016","unstructured":"Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, Dolled-Filhart M, Emancipator K, Stanforth D, Kulangara K (2016) Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol 24:392\u2013397. \n                    https:\/\/doi.org\/10.1097\/PAI.0000000000000408","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2915_CR32","doi-asserted-by":"publisher","DOI":"10.15761\/icst.1000272","author":"O Saglam","year":"2018","unstructured":"Saglam O, Conejo-Garcia J (2018) PD-1\/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther. \n                    https:\/\/doi.org\/10.15761\/icst.1000272","journal-title":"Integr Cancer Sci Ther"},{"key":"2915_CR33","doi-asserted-by":"publisher","first-page":"e0136023","DOI":"10.1371\/journal.pone.0136023","volume":"10","author":"LH Schmidt","year":"2015","unstructured":"Schmidt LH, K\u00fcmmel A, G\u00f6rlich D, Mohr M, Br\u00f6ckling S, Mikesch JH, Gr\u00fcnewald I, Marra A, Schultheis AM, Wardelmann E, M\u00fcller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W (2015) PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One 10:e0136023. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0136023","journal-title":"PLoS One"},{"key":"2915_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ejca.2014.12.006","volume":"51","author":"AM Schultheis","year":"2015","unstructured":"Schultheis AM, Scheel AH, Ozreti\u0107 L, George J, Thomas RK, Hagemann T, Zander T, Wolf J, Buettner R (2015) PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer 51:421\u2013426. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2014.12.006","journal-title":"Eur J Cancer"},{"key":"2915_CR35","doi-asserted-by":"publisher","first-page":"89903","DOI":"10.18632\/oncotarget.20911","volume":"8","author":"JJ Sznurkowski","year":"2017","unstructured":"Sznurkowski JJ, \u017bawrocki A, Sznurkowska K, P\u0119ksa R, Biernat W (2017) PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients. Oncotarget 8:89903\u201389912. \n                    https:\/\/doi.org\/10.18632\/oncotarget.20911","journal-title":"Oncotarget"},{"key":"2915_CR36","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"2915_CR37","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020\u20131030. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.53.0105","journal-title":"J Clin Oncol"},{"key":"2915_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275\u2013287. \n                    https:\/\/doi.org\/10.1038\/nrc.2016.36","journal-title":"Nat Rev Cancer"},{"key":"2915_CR39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R-A, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122\u2013133. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1302369","journal-title":"N Engl J Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02915-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-02915-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02915-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T23:32:10Z","timestamp":1586388730000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-02915-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,10]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2915"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-02915-1","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,10]]},"assertion":[{"value":"20 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AMS, CA und BH are supported by Roche Pharma AG and K\u00f6lner Krebsstiftung. JP was supported by the Else Kr\u00f6ner-Fresenius Stiftung (EKFS-2014-A06 and 2016 Kolleg.19). AHS and RB have participated in advisory boards for BMS, MSD and F. Hoffmann-La Roche AG, pharmaceutical division. FT declares that she has no conflict of interest. BM declares that he has no conflict of interest. CP declares that she has no conflict of interest. LMS declares that he has no conflict of interest. PM declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}